Global REsponsE During iNFusIon of a gEl With LevoDopa/Carbidopa

Launched by ABBVIE (PRIOR SPONSOR, ABBOTT) · Dec 18, 2012

Keywords

ClinConnect Summary

Male or female participants ages 18 years of age who were already on DUODOPA treatment and had concluded the naso-intestinal phase were included in this study. DUODOPA was administered via a portable pump directly into the proximal small intestine via a percutaneous endoscopic transgastric jejunostomy (PEG-J) tube. There were 3 planned visits during the study: enrollment (Visit 1), 1 year (Visit 2), and 2 years (Visit 3).

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants already on treatment with DUODOPA (having already concluded the naso-intestinal treatment phase) according to the local DUODOPA product label and to routine clinical care for advanced PD patients
• • Participants with available data on DUODOPA treatment, on previous PD conventional treatments and with at least one of the scales/questionnaires under study already collected on the participant's clinical chart
• • Participant or legal representative has given written informed consent
• • Non-professional caregiver (relative or familiar who give daily assistance to the patient) has given his/her written consent
• Exclusion Criteria:
• • • History or presence of any condition that might interfere with the long-term continuation of the duodenal infusion of DUODOPA